Physician profile
Stacy C Le
NPI 1841205325
$13,944.01
in general payments reported to CMS, 2019-2025
43 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,848 · 2021: $2,322 · 2022: $2,240 · 2023: $1,923 · 2024: $2,176 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,196.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,991.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,878.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,292.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $705.49 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $703.15 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $689.94 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $672.48 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.41 | 2019-2025 | Jardiance |
| Abbvie INC. | $642.98 | 2021-2025 | |
| Axsome Therapeutics, INC. | $559.06 | 2023-2025 | Auvelity, Symbravo |
| Amarin Pharma, INC. | $482.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $453.93 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $365.07 | 2020-2023 | Nexletol |
| Amgen INC. | $317.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $305.01 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.